to describe the results of treating COVID-19 positive patients with nitazoxanide in three clinical settings: pregnancy/puerperium, hospitalized patients in an Internal Medicine Service and in an ambulatory setting. Methodology: This was a prospective follow-up and report of COVID-19 cases in three different situations, pregnant women, hospitalized patients receiving medical attention in an Internal Medicine Service and ambulatory patients residing in Toluca City, and Mexico City. Results: The experience with a first group of 20 women, pregnant (17) or in immediate puerperium (3) was successful in 18 cases with two unfortunate deaths. The five cases treated in an Internal Medicine service showed a positive outcome with two patients weaned fr...
Abstract Objectives To investigate the efficacy and safety of repurp...
BACKGROUND: The COVER trial evaluated whether nitazoxanide or sofosbuvir/daclatasvir could lower the...
ObjectiveThere is an urgent need for effective treatments to prevent or attenuate lung and systemic ...
Background Nitazoxanide shows adequate in vitro activity against coronavirus. The aim of this study ...
The use of nitazoxanide has previously yielded successful results in vitro against the coronavirus. ...
Introduction: coronavirus pandemic has led to 1.8 million deaths worldwide as of May 1st, 2021. Nita...
SummaryNitazoxanide is a broad-spectrum antiviral agent undergoing clinical development for treatmen...
BackgroundMany treatments are being assessed for repurposing to treat coronavirus disease 2019 (COVI...
Objectives: To determine the efficacy of Hydroxychloroquine vs. Hydroxychloroquine + Nitazoxanide in...
Repurposing approved drugs may rapidly establish effective interventions during a public health cris...
BackgroundThe 2020 pandemic of SARS-CoV-2 causing COVID-19 disease is an unprecedented global emerge...
BACKGROUND: The 2020 pandemic of SARS-CoV-2 causing COVID-19 disease is an unprecedented global emer...
Combined treatments against SARS-CoV-2 are emerging and some have taken into account the post-COVID-...
Funder: UnitaidRepurposing approved drugs may rapidly establish effective interventions during a pub...
Background: The absence of specific antivirals to treat COVID-19 leads to the repositioning of candi...
Abstract Objectives To investigate the efficacy and safety of repurp...
BACKGROUND: The COVER trial evaluated whether nitazoxanide or sofosbuvir/daclatasvir could lower the...
ObjectiveThere is an urgent need for effective treatments to prevent or attenuate lung and systemic ...
Background Nitazoxanide shows adequate in vitro activity against coronavirus. The aim of this study ...
The use of nitazoxanide has previously yielded successful results in vitro against the coronavirus. ...
Introduction: coronavirus pandemic has led to 1.8 million deaths worldwide as of May 1st, 2021. Nita...
SummaryNitazoxanide is a broad-spectrum antiviral agent undergoing clinical development for treatmen...
BackgroundMany treatments are being assessed for repurposing to treat coronavirus disease 2019 (COVI...
Objectives: To determine the efficacy of Hydroxychloroquine vs. Hydroxychloroquine + Nitazoxanide in...
Repurposing approved drugs may rapidly establish effective interventions during a public health cris...
BackgroundThe 2020 pandemic of SARS-CoV-2 causing COVID-19 disease is an unprecedented global emerge...
BACKGROUND: The 2020 pandemic of SARS-CoV-2 causing COVID-19 disease is an unprecedented global emer...
Combined treatments against SARS-CoV-2 are emerging and some have taken into account the post-COVID-...
Funder: UnitaidRepurposing approved drugs may rapidly establish effective interventions during a pub...
Background: The absence of specific antivirals to treat COVID-19 leads to the repositioning of candi...
Abstract Objectives To investigate the efficacy and safety of repurp...
BACKGROUND: The COVER trial evaluated whether nitazoxanide or sofosbuvir/daclatasvir could lower the...
ObjectiveThere is an urgent need for effective treatments to prevent or attenuate lung and systemic ...